GlassScriptPhysician profile
Clinton Philip Dunn
NPI 1730541319
$5,247.01
in general payments reported to CMS, 2019-2025
14 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.38 · 2021: $139 · 2022: $321 · 2023: $4,451 · 2024: $119 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,050 · Food and Beverage: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,050.00 |
| Food and Beverage | $645.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $4,080.47 | 2023 | Odactra, Grastek, Ragwitek |
| Astrazeneca Pharmaceuticals LP | $280.18 | 2021-2023 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $210.27 | 2023-2025 | Dupixent |
| Genzyme Corporation | $146.44 | 2022 | |
| Glaxosmithkline, LLC. | $120.60 | 2023 | Nucala |
| Abbvie INC. | $109.45 | 2023 | Rinvoq |
| Biocryst US Sales Co., LLC | $100.79 | 2022 | |
| Biocryst Pharmaceuticals, INC. | $55.26 | 2024 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $46.22 | 2019 | |
| Csl Behring | $26.85 | 2019 | |
| Leo Pharma INC. | $23.53 | 2022 | |
| Shire North American Group INC | $18.31 | 2019 | |
| Aimmune Therapeutics, INC. | $17.32 | 2022 | |
| Genentech USA, INC. | $11.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clinton Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.